PE20000114A1 - Composiciones de tamano de particula controlado - Google Patents
Composiciones de tamano de particula controladoInfo
- Publication number
- PE20000114A1 PE20000114A1 PE1998001230A PE00123098A PE20000114A1 PE 20000114 A1 PE20000114 A1 PE 20000114A1 PE 1998001230 A PE1998001230 A PE 1998001230A PE 00123098 A PE00123098 A PE 00123098A PE 20000114 A1 PE20000114 A1 PE 20000114A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- particle size
- controlled particle
- composition
- size compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 2
- -1 POLYMETHYLENE Polymers 0.000 abstract 2
- FEAVXMPFTQROEI-UHFFFAOYSA-N 2h-pyrano[3,2-b]pyridine Chemical compound C1=CN=C2C=CCOC2=C1 FEAVXMPFTQROEI-UHFFFAOYSA-N 0.000 abstract 1
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Chemical group 0.000 abstract 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/04—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with unperforated container
- B02C17/06—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with unperforated container with several compartments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/18—Details
- B02C17/20—Disintegrating members
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/18—Details
- B02C17/22—Lining for containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
QUE COMPRENDE UN BENZOPIRANO O PIRIDOPIRANO DE FORMULA I, DONDE Y ES N; R2 ES H o Y ES C-R1, UNO DE R1 Y R2 ES H, EL OTRO ES H, CICLOALQUILO C3-C8, ALQUILO C1-C6; UNO DE R3 Y R4 ES H, ALQUILO C1-C4, EL OTRO ES ALQUILO C1-C4 o R3 Y R4 SON POLIMETILENO C2-C5; R5 ES (ALQUILO C1-C6)CARBONILOXI, BENZOILOXI, BENCILOXI, FENILOXI O ALCOXI C1-C6; R6 Y R9 SON H o R5 ES OH; R6 ES H, ALQUILO C1-C2; R9 ES H; R7 ES FLUOROFENILO; R8 ES H, ALQUILO C1-C6, SIENDO TRANS R8-N-CO-R7 RESPECTO A R5; X ES OXIGENO, NR10; R10 ES H, ALQUILO C1-C6. LA COMPOSICION SE CARACTERIZA POR EL DIAMETRO VOLUMETRICO DE PARTICULAS DE 350 nm A 700 nm. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE SE CARACTERIZA POR TRITURAR EN HUMEDO, EN UN MOLINO DE BOLAS DE DOS CAMARAS CON CIRCULACION DE PRODUCTO ENTRE LAS CAMARAS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE ANSIEDAD, MANIA, DEPRESION, TRASTORNO DE PANICO, AGRESIVIDAD, TRASTORNO ASOCIADOS CON UNA HEMORRAGIA SUBARACNOIDEA, CHOQUE NEURAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9726543.3A GB9726543D0 (en) | 1997-12-16 | 1997-12-16 | Novel compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000114A1 true PE20000114A1 (es) | 2000-04-30 |
Family
ID=10823680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001230A PE20000114A1 (es) | 1997-12-16 | 1998-12-16 | Composiciones de tamano de particula controlado |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP1338274A1 (es) |
| JP (1) | JP2002508310A (es) |
| KR (1) | KR20010033149A (es) |
| CN (2) | CN1284865A (es) |
| AP (1) | AP2000001837A0 (es) |
| AR (1) | AR017212A1 (es) |
| AT (1) | ATE260094T1 (es) |
| AU (1) | AU743155B2 (es) |
| BG (1) | BG104596A (es) |
| BR (1) | BR9813602A (es) |
| CA (1) | CA2314968A1 (es) |
| DE (1) | DE69821978T2 (es) |
| DZ (1) | DZ2677A1 (es) |
| EA (1) | EA003732B1 (es) |
| ES (1) | ES2216350T3 (es) |
| GB (1) | GB9726543D0 (es) |
| HU (1) | HUP0100384A3 (es) |
| ID (1) | ID24930A (es) |
| IL (1) | IL136664A0 (es) |
| MA (1) | MA24721A1 (es) |
| MY (1) | MY132978A (es) |
| NO (1) | NO20003073L (es) |
| NZ (1) | NZ504991A (es) |
| OA (1) | OA11429A (es) |
| PE (1) | PE20000114A1 (es) |
| PL (1) | PL341339A1 (es) |
| SK (1) | SK9132000A3 (es) |
| TR (1) | TR200001792T2 (es) |
| TW (1) | TW200305442A (es) |
| UY (1) | UY25307A1 (es) |
| WO (1) | WO1999030687A1 (es) |
| ZA (1) | ZA9811502B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| EP1294358B1 (en) * | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| GB0112497D0 (en) * | 2001-05-22 | 2001-07-11 | Smithkline Beecham Plc | Formulation |
| GB0127805D0 (en) | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| KR20080066977A (ko) | 2005-11-10 | 2008-07-17 | 더루우브리졸코오포레이션 | 분산체의 제조방법 |
| EP2307004A1 (en) * | 2008-06-05 | 2011-04-13 | Minster Research Limited | Novel treatments |
| JP2011522031A (ja) * | 2008-06-05 | 2011-07-28 | ミンスター・リサーチ・リミテッド | 新規な治療 |
| MX2012006352A (es) * | 2009-12-03 | 2012-06-27 | Proximagen Ltd | Tratamiento de alodinia e hiperalgesia. |
| RU2012124838A (ru) * | 2009-12-03 | 2014-01-10 | Проксимэджен ЛТД | Лечение инфекционных заболеваний |
| EP2471513B1 (en) * | 2010-12-28 | 2015-06-10 | LEK Pharmaceuticals d.d. | Process for producing an active pharmaceutical ingredient (API) preparation in the form of beads |
| WO2016157061A1 (en) * | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5065946A (en) * | 1988-07-21 | 1991-11-19 | Matsushita Electric Industrial Co., Ltd. | Media agitating mill and method for milling ceramic powder |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| NZ258611A (en) * | 1992-12-11 | 1997-07-27 | Smithkline Beecham Plc | 4-benzoyl(or heteroarylcarbonyl)amino-3,4-dihydro- 3-hydroxy-2h-benzo[b]pyran derivatives;benzopyrano[4,3-d]oxazole intermediates |
| HUT76136A (en) * | 1994-06-10 | 1997-06-30 | Smithkline Beecham Plc | Benzopyran compounds and their use as therapeutic agents |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| DE19614295A1 (de) * | 1995-04-21 | 1996-10-24 | Friedrich Dr Ing Vock | Verfahren und Vorrichtung zum Nassmahlen und Dispergieren von Feststoffpartikeln in Flüssigkeiten |
-
1997
- 1997-12-16 GB GBGB9726543.3A patent/GB9726543D0/en not_active Ceased
-
1998
- 1998-11-22 TW TW092109280A patent/TW200305442A/zh unknown
- 1998-12-14 HU HU0100384A patent/HUP0100384A3/hu unknown
- 1998-12-14 WO PCT/EP1998/008156 patent/WO1999030687A1/en not_active Ceased
- 1998-12-14 AT AT98966322T patent/ATE260094T1/de not_active IP Right Cessation
- 1998-12-14 JP JP2000538670A patent/JP2002508310A/ja active Pending
- 1998-12-14 CN CN98813568A patent/CN1284865A/zh active Pending
- 1998-12-14 NZ NZ504991A patent/NZ504991A/xx unknown
- 1998-12-14 EP EP03076016A patent/EP1338274A1/en not_active Withdrawn
- 1998-12-14 AU AU22724/99A patent/AU743155B2/en not_active Ceased
- 1998-12-14 ES ES98966322T patent/ES2216350T3/es not_active Expired - Lifetime
- 1998-12-14 DE DE69821978T patent/DE69821978T2/de not_active Expired - Fee Related
- 1998-12-14 IL IL13666498A patent/IL136664A0/xx unknown
- 1998-12-14 BR BR9813602-0A patent/BR9813602A/pt not_active IP Right Cessation
- 1998-12-14 CA CA002314968A patent/CA2314968A1/en not_active Abandoned
- 1998-12-14 TR TR2000/01792T patent/TR200001792T2/xx unknown
- 1998-12-14 ID IDW20001124A patent/ID24930A/id unknown
- 1998-12-14 PL PL98341339A patent/PL341339A1/xx unknown
- 1998-12-14 EA EA200000664A patent/EA003732B1/ru not_active IP Right Cessation
- 1998-12-14 AP APAP/P/2000/001837A patent/AP2000001837A0/en unknown
- 1998-12-14 SK SK913-2000A patent/SK9132000A3/sk unknown
- 1998-12-14 EP EP98966322A patent/EP1037612B1/en not_active Expired - Lifetime
- 1998-12-14 CN CNA031787088A patent/CN1475206A/zh active Pending
- 1998-12-14 MA MA25390A patent/MA24721A1/fr unknown
- 1998-12-14 KR KR1020007006525A patent/KR20010033149A/ko not_active Ceased
- 1998-12-15 UY UY25307A patent/UY25307A1/es not_active Application Discontinuation
- 1998-12-15 MY MYPI98005667A patent/MY132978A/en unknown
- 1998-12-15 DZ DZ980287A patent/DZ2677A1/xx active
- 1998-12-15 ZA ZA9811502A patent/ZA9811502B/xx unknown
- 1998-12-15 AR ARP980106367A patent/AR017212A1/es not_active Application Discontinuation
- 1998-12-16 PE PE1998001230A patent/PE20000114A1/es not_active Application Discontinuation
-
2000
- 2000-06-15 NO NO20003073A patent/NO20003073L/no not_active Application Discontinuation
- 2000-06-16 OA OA1200000176A patent/OA11429A/en unknown
- 2000-07-11 BG BG104596A patent/BG104596A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000114A1 (es) | Composiciones de tamano de particula controlado | |
| NO971965L (no) | Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav | |
| Perry et al. | Effect of doxycycline hyclate on corneal epithelial wound healing in the rabbit alkali-burn model: preliminary observations | |
| EP0590604A3 (en) | Hairsprays and acrylic polymer compositions for use therein | |
| BR0012387A (pt) | Composição para tratamento de distúrbios de secreção externa | |
| EP0527801A4 (en) | Thiophene sulfonamides useful as carbonic anydrase inhibitors | |
| ATE204460T1 (de) | Gelstiftzusammensetzung enthaltend gebildner angereichert in optisch aktiver form | |
| NO953187D0 (no) | Imidazopyridiner og deres anvendelse ved behandling av mave-tarm-sykdommer | |
| BR0010648A (pt) | Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril | |
| MXPA01008058A (es) | Composiciones deinhibidor de cicloxigenasa-2 teniendo un rapido inicio de efecto terapeutico. | |
| HUT72670A (en) | Containing galanthamine pharmaceutical composition for treating nicotine dependence | |
| FR2719769B1 (fr) | Composition cosmétique ou dermatologique sous forme d'huile gélifiée contenant un mélange d'acide hydroxy-12 stéarique ou d'un dialkylamide de l'acide N-lauroylglutamique et d'un copolymère styrène/alcadiène hydrogéné. | |
| GR1002486B (el) | Νεα κρυσταλλικη μορφη κυκλοσπορινης, μεθοδος παραγωγης της,φαρμακευτικες συνθεσεις περιεχουσες αυτη και η χρησις της. | |
| PL350123A1 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
| AR086688A2 (es) | Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento | |
| BG108180A (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| DK0598365T3 (es) | ||
| ZA936504B (en) | Pharmaceutical composition for topical application to the eye for treating increased intraocular pressure. | |
| BR9808722A (pt) | Composições farmacêuticas de tizoxanida e nitazoxanida | |
| ES2031916T3 (es) | Un producto antitranspirante solido. | |
| GB0105837D0 (en) | Pharmaceutical compositions including alginates | |
| LV11272A (lv) | Terapeitiska kompozicija | |
| MX9300203A (es) | Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene. | |
| MX9300205A (es) | Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene. | |
| CO4750820A1 (es) | Composiciones que contienen un activo farmaceutico analge- sico y un agente antihistaminico de eter de pirrolidina o piperidina y, opcionalmente, un compuesto alfa-agonista y/o cafeina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |